Theratechnologies (NASDAQ:THTX) Trading 0.5% Higher - Here's Why

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report)'s stock price traded up 0.5% on Wednesday . The stock traded as high as $2.78 and last traded at $2.76. 383,922 shares traded hands during trading, a decline of 52% from the average session volume of 799,915 shares. The stock had previously closed at $2.74.

Analyst Ratings Changes

A number of research firms have weighed in on THTX. Research Capitl upgraded shares of Theratechnologies to a "strong-buy" rating in a research report on Friday, February 14th. Jones Trading upgraded Theratechnologies from a "hold" rating to a "strong-buy" rating in a research report on Friday, April 11th.

Theratechnologies Stock Down 4.4 %

The firm has a market cap of $120.47 million, a PE ratio of -26.20 and a beta of 0.56. The business has a 50 day simple moving average of $2.02 and a two-hundred day simple moving average of $1.71.

Hedge Funds Weigh In On Theratechnologies

Several institutional investors have recently made changes to their positions in the company. Hillsdale Investment Management Inc. bought a new position in Theratechnologies during the 4th quarter worth about $108,000. Cyndeo Wealth Partners LLC purchased a new position in Theratechnologies during the first quarter valued at approximately $42,000. Virtu Financial LLC bought a new position in Theratechnologies in the fourth quarter worth approximately $40,000. BNP Paribas Financial Markets bought a new position in Theratechnologies in the fourth quarter worth approximately $36,000. Finally, Wealthspire Advisors LLC lifted its holdings in Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock worth $129,000 after buying an additional 20,000 shares during the period.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.